113 related articles for article (PubMed ID: 16527606)
1. Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization.
Gomez GG; Varella-Garcia M; Kruse CA
Cancer Genet Cytogenet; 2006 Mar; 165(2):121-34. PubMed ID: 16527606
[TBL] [Abstract][Full Text] [Related]
2. Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.
Gomez GG; Kruse CA
J Immunother; 2007 Apr; 30(3):261-73. PubMed ID: 17414317
[TBL] [Abstract][Full Text] [Related]
3. Immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes: downregulation of multiple proapoptotic factors.
Gomez GG; Hickey MJ; Tritz R; Kruse CA
Gene Ther Mol Biol; 2008 Jun; 12(1):101-110. PubMed ID: 19066635
[TBL] [Abstract][Full Text] [Related]
4. Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modification.
Read SB; Kulprathipanja NV; Gomez GG; Paul DB; Winston KR; Robbins JM; Kruse CA
J Interferon Cytokine Res; 2003 Jul; 23(7):379-93. PubMed ID: 14511464
[TBL] [Abstract][Full Text] [Related]
5. Gamma interferon transduced 9L gliosarcoma. Cytokine gene therapy and its relevance to cellular therapy with alloreactive cytotoxic T lymphocytes.
Paul DB; Read SB; Kulprathipanja NV; Gomez GG; Kleinschmidt-DeMasters BK; Schiltz PM; Kruse CA
J Neurooncol; 2003; 64(1-2):89-99. PubMed ID: 12952290
[TBL] [Abstract][Full Text] [Related]
6. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics.
Kronik N; Kogan Y; Vainstein V; Agur Z
Cancer Immunol Immunother; 2008 Mar; 57(3):425-39. PubMed ID: 17823798
[TBL] [Abstract][Full Text] [Related]
7. Effects of IFN-gamma and interleukin-1beta on major histocompatibility complex antigen and intercellular adhesion molecule-1 expression by 9L gliosarcoma: relevance to its cytolysis by alloreactive cytotoxic T lymphocytes.
Schiltz PM; Gomez GG; Read SB; Kulprathipanja NV; Kruse CA
J Interferon Cytokine Res; 2002 Dec; 22(12):1209-16. PubMed ID: 12581494
[TBL] [Abstract][Full Text] [Related]
8. Microglia phagocytose alloreactive CTL-damaged 9L gliosarcoma cells.
Kulprathipanja NV; Kruse CA
J Neuroimmunol; 2004 Aug; 153(1-2):76-82. PubMed ID: 15265665
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy.
Liu G; Akasaki Y; Khong HT; Wheeler CJ; Das A; Black KL; Yu JS
Oncogene; 2005 Aug; 24(33):5226-34. PubMed ID: 15897911
[TBL] [Abstract][Full Text] [Related]
10. Cellular immunity in the treatment of brain tumors.
Wheeler CJ; Yu JS; Black KL
Clin Neurosurg; 2004; 51():132-9. PubMed ID: 15571138
[No Abstract] [Full Text] [Related]
11. Interleukin 2-activated cytotoxic lymphocytes in cancer therapy.
Grimm EA; Jacobs SK; Lanza LA; Melin G; Roth JA; Wilson DJ
Symp Fundam Cancer Res; 1986; 38():209-19. PubMed ID: 3489259
[TBL] [Abstract][Full Text] [Related]
12. Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma.
Kobayashi T; Yamanaka R; Homma J; Tsuchiya N; Yajima N; Yoshida S; Tanaka R
Cancer Immunol Immunother; 2003 Oct; 52(10):632-7. PubMed ID: 12827308
[TBL] [Abstract][Full Text] [Related]
13. [Cellular immunotherapy for malignant glioma].
Okamoto Y; Yamashita J
Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
[No Abstract] [Full Text] [Related]
14. Immunomonitoring in glioma immunotherapy: current status and future perspectives.
Lamano JB; Ampie L; Choy W; Kesavabhotla K; DiDomenico JD; Oyon DE; Parsa AT; Bloch O
J Neurooncol; 2016 Mar; 127(1):1-13. PubMed ID: 26638171
[TBL] [Abstract][Full Text] [Related]
15. Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.
Wang JY; Bettegowda C
J Neurooncol; 2015 Jul; 123(3):373-83. PubMed ID: 25697584
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
Holladay FP; Heitz T; Wood GW
J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
[TBL] [Abstract][Full Text] [Related]
17. A novel recombinant protein of IP10-EGFRvIIIscFv and CD8(+) cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice.
Wang X; Lu XL; Zhao HY; Zhang FC; Jiang XB
Cancer Immunol Immunother; 2013 Jul; 62(7):1261-72. PubMed ID: 23640602
[TBL] [Abstract][Full Text] [Related]
18. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade human glioma.
Coons SW; Johnson PC; Shapiro JR
Cancer Res; 1995 Apr; 55(7):1569-77. PubMed ID: 7882367
[TBL] [Abstract][Full Text] [Related]
20. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
